Connect with us:     
Skip Navigation Links

Alan Menter, MD

 

 

Chief, Division of Dermatology

Baylor University Medical Center, Dallas TX

 

Clinical Professor of Dermatology

University of Texas, Southwestern Medical School

 

Director, Fellowship Program

Baylor Psoriasis Center, Dallas TX

 

Chair, Psoriasis Guidelines Committee, American Academy of Dermatology

 

Director, Dermatology Residency Program

Baylor University Medical Center

 

 

Contact Information  

3900 Junius Street Suite 125

Dallas TX 75246

 

(972) 386-7546 phone

(972) 661-3255 fax

 

E-mail General: amderm@gmail.com

E-mail Research: alanmresearch@gmail.com

 

 

Education                  

University of Witwatersrand, Johannesburg, South Africa

Medical Student (1959-1966)

                       

Internships

Department of Medicine, Johannesburg General Hospital (1967)

Department of Surgery, Johannesburg General Hospital (1967)                

Sr Intern, Medicine/Dermatology, Johannesburg Gen Hospital (1968)

                                               

Residency                    

Department of Dermatology, University of Pretoria

Pretoria (South Africa) General Hospital (1968-1971)

 

Fellowships                  

Guy’s Hospital, London, England (1971-1972)

St. John’s Hospital for Diseases of the Skin, London (1972-1973)

University of Texas Southwestern Medical School, Dallas TX (1977-1979)

 

 

Major Contributions to Science 

 

1.  First Gene Bank for Psoriasis. The National Psoriasis Gene Bank was originally based at the   clinic at Baylor, Dallas with Alan Menter, M.D. as Clinical Director. Families with psoriasis were assembled from all over the U.S. and blood samples taken to research the genetic basis for psoriasis. The first International Consortium meeting for the Genetics of Psoriasis was held in Dallas, sponsored by the National Psoriasis Foundation in 1994.

 

  • Tomforhde J, Silverman A, Barnes R, Fernandez-Vina MA, Young M, Lory D, Morris LF, Wuepper KD, Stastny P, Menter A, Bowcock A. Gene for familial psoriasis: susceptibility mapped to the distal end of human chromosome 17q. Science 1994;264:1141-45.

 

2.  Chair of the American Academy of Dermatology work group who developed the 6 AAD Guidelines of care for the management of psoriasis and psoriatic arthritis.

 

  • Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis.  Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50.
  • Gottlieb A, Korman NJ, Gordon K, Menter A, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-864.
  • Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009;60:643-59.
  • Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-85.
  • Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis.  Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 2010;62:114-35.
  • Menter A, Korman, NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011;65:137-74.     

 

3.  Dr. Alan Menter founded the International Psoriasis Council (IPC), an international organization dedicated to raising international consciousness and understanding of psoriasis as a serious immune-mediated disease with major quality of life implications. The organization is committed to advancing psoriasis research and treatment.  IPC provides a forum for collaboration, innovation and education among physicians, researchers and other medical professionals. Working together on the medical, social and economic aspects of psoriatic disease, IPC advances the standard of care Dr. Menter served as the initial President of IPC from 2004 until December 2010.  He currently serves on the board as the Immediate Past President.

 

4.  Dr. Menter is President of the 3rd World Psoriasis and Psoriatic Arthritis Conference to be held in Stockholm in 2012, organized by the International Federation of Psoriasis Associations (IFPA).

 

 

Research Grants 

 

Abbott Laboratories

Allergan, Inc.

Allermed

Amgen, Inc.

Asubio

Berlex, Inc.

Biogen Idec

Centocor, Inc.

Cephalon

Celgene

Collagenex Pharmaceuticals

CombinatoRx

Connetics Corporation

Corixa Corporation

Dermik Laboratories

Doak Dermatologics

Dow

DUSA

Eli Lilly

Ferndale Laboratories, Inc.

Fujisawa Healthcare, Inc.

Galderma

Genentech, Inc.

Genzyme

GlaxoSmithKline

Ligand Pharmaceuticals 

Medicis

MedImmune, Inc.

National Institutes of Health

National Psoriasis Foundation

Novartis Pharmaceuticals

Otsuka Pharmaceutical, Inc.

Pfizer

Promius Pharma

Protein Design Labs

QLT, USA

Regeneration Pharma AG

Roche Laboratories

Serono

Sinclair

Stiefel

Synta Pharma

Thermosurgery

3 M Pharmaceuticals

UCB

Vertex

Warner Chilcott

Wyeth

XOMA

Zars, Inc.

 

 

 

Key Publications (past 5 years)

 

Books

1.  Menter A, Smith C, Barker J. Fast Facts-Psoriasis, 3rd ed. Abingdon, Oxfordshire, UK: Health Press Limited; 2008.

2.  Menter A, Stoff  B. Psoriasis. Manson Publishing Ltd, London; 2010.

 

Book Chapters 

1.  Weinstein GD, Mentor A. An overview of psoriasis. In Koo JYM, Chai SL, Lebwohl MG, Gottlieb AB, eds. Moderate-to-Severe Psoriasis. 3rd ed.; Informa Healthcare USA Inc, New York NY; 2008:1-26.

2.   Culp B, Mentor A. Efalizumab in the treatment of psoriasis. In Koo JYM, Chai SL, Lebwohl MG, Gottlieb AB, eds. Moderate-to-Severe Psoriasis. 3rd ed.; Informa Healthcare USA Inc, New York; 2008:307-26. 

3.  Culp B, Mentor A. Efalizumab in the treatment of psoriasis. In Weinstein GD, Gottlieb AB eds. Therapy of Moderate-to-Severe Psoriasis. 3rd ed.; Taylor & Francis, New York; 2011. 

4.  Weinstein GD, Mentor A. An overview of psoriasis. In Weinstein GD, Gottlieb AB, eds. Therapy of Moderate-to-Severe Psoriasis. 3rd ed.; Taylor & Francis, New York; 2011. 

5.  Heller MM, Wong JW, Nguyen TV, Lee ES, Bhutani T, Mentor A, Koo JYM. Quality-of-life instruments: evaluation of the impact of psoriasis on patients. In Thiers BH, Chen SC, eds.Quality of Life Issues in Dermatology. Dermatologic Clinics; Elsevier Saunders; 2012.  

 

Journal Articles

1.  Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007 Jan; 56(1):31.e1-e15.

 

2.  Griffiths CEM, Christophers E, Barker JNWN, Chalmers RJG, Chimenti S, Krueger GG, Leonardi C, Menter AM, Ortonne JP, Fry L. A classification of psoriasis according to phenotype. Br J Dermatol 2007 Feb;156:258-62.

 

3.  Lebwohl M, Menter A, Weiss J, Clark SD, Flores J, Powers J, Balin AK, Kempers S, Glinert RJ, Fleming T, Liu Y, Graeber M, Pariser DM. Calcitriol 3mG/G ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol 2007; 6(4):428-35.

 

4.  Menter A, Hamilton TK, Toth DP, Leung HM, Wetherill G, Hennessey B, et al. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, phase IIIb study. Int J Dermatol 2007; 46:637-48.

 

5.  Schlessinger J, Menter A, Gold M, Leonardi C, Eichenfeld L, Plott RT, Leyden J, Wortzman M; ZIANA Study Group. Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol 2007 Jun;6(6):607-15.

 

6.  Sterry W, Strober BE, Menter A; International Psoriasis Council. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007 Oct;157(4):649-55.

 

7.  Koo J, Menter A, Feldman S, Lebwohl M. The COBRA Trial: a large-scale community-based trial on moderate and severe psoriasis. Cutis 2007 Nov;80:5S.

 

8.  Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007 Jul;370(9583):272-84.

 

9.  Menter A. Topical monotherapy with clobetasol propionate spray 0.05% in the COBRA trial. Cutis 2007 Nov;80(5 Suppl):12-9.

 

10.  Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley, RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008 Jan;58(1):106-15.

 

11.  Perlmutter A, Cather J, Franks B, Jaracz, E, Menter A.  Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis. J Am Acad Dermatol 2008 Jan;58(1):116-24.      

 

12.  Revicki DA, Willian MK, Menter A, Saurat J-H, Harnam N, Kaul M. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology 2008;2163):260-70.

 

13.  Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J; ABT-874 Psoriasis Study Investigators. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008 Feb;144(2):200-7.

 

14.  Liu YC, Helms, C, Liao W, Zaba LC, Duan S, Gardner J, Wise C, Miner A, Malloy MJ, Pullinger , Kane J, Saccone S, Worthington J, Bruce I, Kwok PY, Menter A, Krueger J, Barton A, Saccone NL, Bowcock AM. A genome-wide association study of psoriasis and psoriatic arthritis identifies new loci. PLoS Genet 2008 Mar;4(3):e1000041.

 

15.  Veraldi S, Menter A, Innocenti M. Treatment of mild to moderate seborrhoeic dermatitis with MAS064D (Sebclair®), a novel topical medical device: results of a pilot, randomized, double-blind, controlled trial. J Eur Acad Dermatol Venereol 2008 Mar;22(3):290-6.

 

16.  Kircik L, Bagel J, Korman N, Menter A, Elmets CA, Koo J, Yang Y-C, Chiou C-F, Dann F, Stevens SR. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol 2008 Mar;7(3):245-53.

 

17.  Menter A, Gottlieb A, Feldman S, Van Vorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JYM, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008 May;58(5):826-50.

 

18.  Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JYM, Van Vorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008 May; 58(5):851-64.

 

19.  Smith EC, Riddle C, Menter MA, Lebwohl M. Combining systemic retinoids with biologic agents for moderate to severe psoriasis. Int J Dermatol 2008 May;47(5):514-8.

 

20.  Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB. Efalizumab: results of a 3-year continuous dosing study for long-term control of psoriasis. Br J Dermatol 2008 May;158:1107-16.

 

21.  Menter A, Vamvakis G, Jorizzo J. One-week treatment with once-daily fluorouracil cream 0.5% in participants with actinic keratoses. Cutis 2008;81:509-16.

 

22.  Gordon KB, Blum RR, Papp KA, Matheson R, Bolduc C, Hamilton T, Heffernan M, Menter A, Okun M, Zhong J, Kaul M, Camez A. Efficacy and safety of adalimumab treatment in patients with moderate to severe psoriasis: a double-blind, randomized clinical trial. Psoriasis Forum 2008;13(1):4-12.

 

23.  Reich K, Menter A, Plotnick M, Guzzo C, Li S, Gottlieb A. Consistency of infliximab response across subgroups of patients with psoriasis: integrated results from randomized clinical trial. Psoriasis Forum 2008;13(1):21-33.

 

24.  Van de Kerkhof PCM, Barker J, Griffiths CE, Kragballe K, Mason J, Menter A, Papp K. Psoriasis: consensus on topical therapies. J Eur Acad Dermatol Venereol 2008 Jul;22(7):859-70.

 

25.  Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta analysis of randomized controlled trials. Br J Dermatol 2008:274-85.

 

26.  Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, Li S, Dooley LT, Menter A. Infliximab improves heath-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol 2008 Sep;159(3):707-10.

 

27.  Gottlieb AB, Dann F, Menter A. Psoriasis and the metabolic syndrome. J Drugs Dermatol 2008 Jun;7(6):563-72.

 

28.  Kourosh S, Miner A, Menter A. Psoriasis as the marker of underlying systemic disease. Skin Therapy Lett 2008 Feb;13(1):1-5.

 

29.  Warren RB, Chalmers RJG, Griffiths CEM, Menter A. Methotrexate for psoriasis in the era of biological therapy. Clin Exp Dermatol 2008;33:551-4.

 

30.  Hamilton T, Menter A, Caro I, Compton P, Sobell J, Papp KA. Safety of efalizumab therapy in patients with moderate to severe psoriasis: an open-label extension of a phase IIIb trial. Drug Saf 2008;31(8):715-26.

 

31.  Feldman SR, Horn EJ, Balkrishnan R, Basra MK, Finlay AY, McCoy D, Menter A, van de Kerkhof PCM. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol 2008;59(6):1009-16.

 

32.  Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled phase III study. Health Qual Life Outcomes 2008 Oct;6:75.

 

33.  Strober BE, Menter A, Crowley J. Long-term safety and efficacy in the treatment of psoriatic conditions. Practice with the Experts 2008 Dec;2(4).

 

34.  Perlmutter A, Mittal A, Menter A. Tuberculosis and tumour necrosis factor-α inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. Br J Dermatol 2009;160:8-15.

 

35.  Nair RP, Duffin Callis K, Helms , Ding J, Stuart PE, Goldgar D, Gudjonsson JE, Li Y, Tejasvi T, Feng BJ, Ruether A, Schreiber S, Weichenthal M, Gladman D, Rahman P, Schrodi SJ, Prahalad S, Guthery SL, Fischer J, Lioa W, Kwok P-Y, Menter A, Lathrop GM, Wise CA, Begovich AB, Voorhees JJ, Elder JT, Krueger GG, Bowcock AM, Abecasis GR; Collaborative Association Study of Psoriasis. Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nat Genet 2009;41:199-204.

 

36.  Menter A, Reich K, Gottlieb AB, Bala M,  Li S, Hsu M-C, Guzzo C, Diels J, Gelfand JM. Adverse drug events in infliximab-treated patients compared with the general psoriasis population. J Drugs Dermatol 2008 Dec;7(12):1137-46.

 

37.  Gottlieb A, Menter A, Mendelsohn A, Shen Y-K, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009 Feb;373(9664):633-40.

 

38.  Menter A, Abramovits W, Colon LE, Johnson LA, Gottschalk RW. Comparing clobetasol, propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. J Dr Dermatol 2009 Jan;8(1):52-7.

 

39.  Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Lim HW, Van Vorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009 Apr;60(4):643-59.

 

40.  Ul Ain Kamili Q, Menter A. Psoriasis in the pediatric patient. Pediatric Society of Greater Dallas, First Quarter 2009(Feb):10-14.

 

41.  Boltan LE, Menter A. Pustules and dystrophy of the nails. Proc (Bayl Univ Med Cent) 2009 Apr;22(2):162-3.

 

42.  Farley E, Masrour S, McKey J, Menter A. Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol 2009 Jun;60(6):1024-31.

 

43.  Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb A, Horn EJ, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Menter A, Schwartzman S, Sobell JM, Young MA. Series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol 2009 Jul; 61(1 Suppl 1):S1-S46.

 

44.  Menter A, ul Ain Kamili Q, Farley E. Get under the skin – diagnosis and treatment of psoriasis and guidelines for specialists. Medical Economics July 2009

 

45.  Miner A, Menter A. The ethics of consulting with pharmaceutical companies. Clin Dermatol 2009;27:339-45.

 

46.  Larsen F, Menter A, Cockerell CJ, Wilcox BN. Verrucous linear (segmental) psoriasis of the right leg responding to radiation therapy. J Drugs Dermatol 2008 Oct;7(10):969-71.

 

47.  Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Honigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD,Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de Kerkhof P, Rzany B. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009 Oct;23 Suppl 2:1-70.

 

48.  Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R.  Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009 Sep;61(3):451-85.

 

49.  ul Ain Kamili Q, Menter A. Genetics of psoriasis and psoriatic arthritis. Psoriasis Forum 2009:15(1):8-12.

 

50.  ul Ain Kamili Q, Menter A. Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy. J Drugs Dermatol 2010 Jan;9(1):57-90.

 

51.  Tebbey P, Romiti R, Prens E, Menter A. The International Psoriasis Council presents top 2009 research articles. Psoriasis Forum 2009;15(2):24-32.

 

52.  Menter A, Korman NJ, Elmets CA, Feldman SR, et al.  Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009 Apr;60(4):643-59.

 

53.  Horn EJ, Chambers CD, Menter A, Kimabll A; IPC. Pregnancy outcomes in psoriasis: why do we know so little? J Am Acad Dermatol 2009 Aug;61(2):e5-8.

 

54.  Menter A, Korman NJ, Elmets CA, Feldman SR, et al.  Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009 Sep;61(3):451-85 .

 

55.  Menter A. The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis 2009 Oct;84(4 Suppl):14-24.

 

56.  Kamili QU, Menter A. Topical treatment of psoriasis. Curr Probl Dermatol 2009;38:37-58.

 

57.  Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A; ACCEPT Study Group. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010 Jan;362(2):118-28.

 

58.  Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. Semin Cutan Med Surg 2010 Mar;29(1):10-5.

 

59.  Ryan C, Thrash B, Warren RB, Menter A. The use of ustekinumab in autoimmune diseases. Expert Opin Biol Ther 2010 Apr;10(4):587-604.

 

60.  Ryan C, Menter A, Warren RB. The latest advances in pharmacogenetics and pharmacogemonics in the treatment of psoriasis. Mol Diagn Ther 2010 Apr;14(2):81-93.

 

61.  Menter A, Augustin M, Signorovitch J, Yu A, Wu E, Gupta SR, Bao Y, Mulani P. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol 2010 May;62(5):812-8.

 

62.  Hollmig T, Menter A. Familial coincidence of hidradenitis suppurativa and steatocystoma multiplex. Clin Exp Dermatol 2010 Jun;35(4):e151-2.

 

63.  Menter A, Gordon K, Leonardi C. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol 2010 Sep;63(3):448-56.

 

64.  Kavanaugh A, Menter A, Mendelsohn A, Shen SK, Lee S, Gottlieb A. Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. Curr Med Res Opin 2010 Oct;26(10):2385-92.

 

65.  Zeichner J, Lebwohl M, Menter A, Bagel J, DelRosso J, Elewski B, Feldman S, Kircik L, Koo J, Stein Gold L, Tanghetti E. Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis 2010;86:3S.

 

66.  Menter A, Griffiths CEM, Tebbey PW, Horn EJ, Sterry W; International Psoriasis Council. Exploring the association between cardiovascular and other disease related risk factors in the psoriasis population: the need for increased understanding across the medical community. J Eur Acad Dermatol Venereol 2010 Dec;24(12):1371-7.

 

67.  Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: Part I. J Amer Acad Dermatol 2010 Dec;63(6):925-46.

 

68.  Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: Part II. J Amer Acad Dermatol 2010 Dec;63(6):949-72.

 

69.  Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol 2010 Sep;63(3):448-56.

 

70.  Del Rosso JQ, Bruce S, Jarratt M, Menter A, Staedtler G. Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea. J Drugs Dermatol 2010 Jun;9(6):607-13.

 

71.  Kavanaugh A, Menter A, Mendelsohn A, Shen YK, Lee S, Gottlieb AB. Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. Curr Med Res Opin 2010 Oct;26(10):2385-92.

 

72.  van de Kerkhof P, Barker J, Griffiths CE, Menter A, Leonardi C, Young M, Kemeny L, Pincelli C, Bachelez H, Katsambas A, Ståhle M, Horn EJ, Sterry W; International Psoriasis Council. Improving clinical trial design in psoriasis: perspectives from the global dermatology community. J Dermatol Treat 2011 Aug;22(4):187-93.

 

73.  Zeichner JA, Lebwohl MG, Menter A, Bagel J, Del Rosso JQ, Elewski BE, Feldman SR, Kircik LH, Koo J, Gold LS, Tanghetti E; Psoriasis Process of Care Consensus Panel. Optimizing topical therapies for treating psoriasis: a consensus conference. Cutis 2010 Sep;86(3 Suppl):5-31; quiz 32.

 

74.  Amor KT, Ryan C, Menter A. The use of cyclosporine in dermatology: part I. J Am Acad Dermatol 2010 Dec;63(6):925-46; quiz 947-8. Review.

 

75.  Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: part II. J Am Acad Dermatol 2010 Dec;63(6):949-72; quiz 973-4. Review.

 

76.  Kimball AB, Gordon KB, Langley RG, Menter A, Perdok RJ, Valdes J; ABT-874 Study Investigators. Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. J Am Acad Dermatol 2011;64(2):263-74.

 

77.  American Academy of Dermatology Work Group, Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Leonardi CL, Lim HW, Van Voorhees AS, Beutner KR, Ryan C, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011 Jul;65(1):137-74.

 

78.  Farley E, Menter A. Psoriasis: comorbidities and associations. G Ital Dermatol Venereol 2011 Feb;146(1):9-15.

 

79.  Kamili QU, Miner A, Hapa A, Menter A. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review. J Drugs Dermatol 2011 May;10(5):539-44.

 

80.  Wittkowski KM, Leonardi C, Gottlieb A, Menter A, Krueger GG, Tebbey PW, Belasco J, Soltani-Arabshahi R, Gray J, Horn L, Krueger JG; International Psoriasis Council. Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis. PLoS One 2011;6(6):e20279.

 

81.  Menter A, Sofen H, Smith S, Papp K, Kempers S, Hudson CP, Colón LE, Johnson LA, Gottschalk R. An open-label, multicenter study of the efficacy and safety of an AM/PM treatment regimen with clobetasol propionate spray 0.05% and calcitriol ointment 3 microg/g in the management of plaque psoriasis. Cutis 2011 Jul;88(1):46-51.

 

82.  Joyce CE, Zhou X, Xia J, Ryan C, Thrash B, Menter A, Zhang W, Bowcock AM.

Deep sequencing of small RNAs from Hum Mol human skin reveals major alterations in the psoriasis miRNAome. Genet 2011 Oct ;20(20):4025-40.

 

83.  Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de Lemos JA, Daoud Y, Blankenship D, Kazi S, Kaplan DH, Friedewald VE, Menter Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. Jama 2011 Aug;306(8):864-71.

 

84.  Hudson CP, Kempers S, Menter A, Papp K, Smith S, Sofen H, Colón LE, Johnson LA, Gottschalk R. An open-label, multicenter study of the efficacy and safety of a weekday/weekend treatment regimen with calcitriol ointment 3 microg/g and clobetasol propionate spray 0.05% in the management of plaque psoriasis. Cutis 2011 Oct;88(4):201-7.

 

85.  Abramson A, Menter A. An unusual facial ulcer. Proc (Bayl Univ Med Cent) 2012 Jan;25(1):85-6.

 

86.  Dhaliwal S, Patel M, Menter A. Secondary syphilis and HIV. Proc (Bayl Univ Med Cent) 2012 Jan;25(1):87-9.

 

87.  Menter MA. Clobetasol propionate spray 0.05% for the treatment of moderate to severe plaque psoriasis. Cutis 2012 Feb;89(2):89-94.

 

88.  Strober BE, Armour K, Romiti R, Smith C, Tebbey PW, Menter A, Leonardi C. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. J Am Acad Dermatol 2012 Feb;66(2):317-22.

 

89.  Roberson ED, Liu Y, Ryan C, Joyce CE, Duan S, Cao L, Martin A, Liao W, Menter A, Bowcock AM. A subset of methylated CpG sites differentiate psoriatic from normal skin. J Invest Dermatol 2012 Mar;132(3):583-92.

 

90.  Heller MM, Wong JW, Nguyen TV, Lee ES, Bhutani T, Menter A, Koo JY. Quality-of-life instruments: evaluation of the impact of psoriasis on patients. Dermatol Clin 2012 Apr;30(2):281-91.

 



Baylor Health Care System is located in Dallas, Texas